Algiecel Scales Up: Danish Greentech Pioneers Industrial-Grade Microalgae Production Amid Global Fish Oil Crises

COPENHAGEN, DENMARK — In a milestone development for both the global biotechnology sector and sustainable supply chains, Danish microalgae innovator Algiecel has officially inaugurated its new industrial-scale production facility. Recognized by TIME and Statista as one of the World’s Top GreenTech Companies of 2026, Algiecel is stepping out of the pilot phase and into full commercial deployment.

The new plant is strategically situated within Novonesis’ sprawling Kalundborg site—widely acknowledged as one of the largest and most advanced enzyme manufacturing hubs in the world. This move represents a decisive shift from sample-volume testing to the reliable, high-volume industrial supply of premium marine ingredients. Crucially, Algiecel’s proprietary technology decouples omega-3 and marine-based nutrients from traditional wild-catch fishing and fish-dependent supply chains, offering a timely alternative to industries facing acute raw material shortages.

Main Facts: Breaking the Mold with Circular Biotechnology

Algiecel’s expansion into the Kalundborg facility is more than just a physical relocation; it is a fundamental scaling of its operational capacity.

• Fivefold Capacity Increase: The new industrial reactor boasts a total volume of 5,500 liters, with 3,240 liters actively dedicated to growing microalgae. This dwarfs the company’s previous 700-liter pilot system.
• Industrial Integration: Rather than operating in a sterile laboratory bubble or relying on commercially bottled gases, the facility utilizes real, captured carbon dioxide ($textCO_2$) piped directly from an operational biogas plant located on-site at Kalundborg.
• Modular Scalability: Algiecel’s engineering philosophy relies on adding identical, modular units rather than attempting to re-engineer a massive, single-vessel system. This ensures a predictable, repeatable path to continuous capacity expansion as market demand dictates.
• Target Sectors: Beginning in 2027, the company expects to produce 12 tonnes of high-grade biomass annually, targeting the rapidly growing pet food and cosmetics markets.
• Financial Backing: The opening of this facility follows a successful DKK 60 million (approximately $9 million USD) funding round closed in 2024, alongside recent high-profile executive and board appointments that have fortified the company’s governance and financial stewardship.

Chronology: The Journey from Concept to Industrial Reality

Understanding Algiecel’s rise requires tracking a strategic trajectory of technological refinement, financial mobilization, and infrastructure partnerships.

The Foundation and Pilot Phase (Pre-2024)

For years, Algiecel operated its pilot-scale reactor, accumulating more than 10,000 operational hours. During this extensive testing period, the company demonstrated that its proprietary biological processes could perform reliably under real-world conditions, proving the resilience and efficiency of its microalgae strains.

Capital Infusion (2024)

To transition from a promising lab-scale concept to a commercial enterprise, Algiecel secured DKK 60 million ($9 million USD) in funding during 2024. This capital laid the groundwork for engineering the industrial-scale modular reactors and forging key industrial partnerships.

Executive and Board Restructuring (Early 2026)

Recognizing the need for seasoned industrial leadership to navigate a heavy industrial scale-up, Algiecel bolstered its executive team and board of directors:

• Tove Feld was appointed Chair of the Board. Feld brings heavy-hitting engineering and corporate governance experience, having previously served as Chief Technology Officer and Head of Engineering at Ørsted and Siemens Wind Power, alongside board roles at The Renewables Infrastructure Group (TRIG) and DHI.
• Mette Ingeman Pedersen stepped in as Chief Financial Officer. Pedersen brings deep financial acumen from her previous tenure as CFO of Topsoe’s Power-to-X business, as well as senior leadership roles at Saxo Bank and Nordea.

The Kalundborg Inauguration (Late 2026)

The culmination of years of R&D, financial planning, and structural recruitment materialized with the opening of the Kalundborg facility inside the Novonesis manufacturing ecosystem. This transition marks the official boundary where Algiecel moves from promising green startup to an active player in industrial supply chains.

Supporting Data: The Perfect Storm in Global Omega-3 Markets

Algiecel’s commercial debut arrives against a backdrop of severe volatility and tightening supply constraints within traditional marine ingredient markets.

The Fish Oil Crunch

Global fish oil supplies are currently experiencing acute structural stress. According to data from the Marine Ingredients Organisation (IFFO), cumulative fish oil production across the world’s leading producing regions—including Peru, Chile, Iceland, the Faroe Islands, the UK, Denmark, and Norway—was running roughly 31% below 2025 year-to-date levels by early June 2026.

To compound matters, meteorological forecasters at the World Meteorological Organization (WMO) identified a newly developing El Niño event for the 2026–2027 season in June 2026. Historically, El Niño weather patterns disrupt marine ecosystems in the Pacific, driving wild-catch fish stocks down and pushing fish oil prices to unprecedented record highs.

Market Projections and Vulnerabilities

Fish oil remains a foundational raw material across multiple lucrative verticals, most notably in high-end pet food formulation and premium cosmetic product manufacturing. As wild-catch volatility deepens, manufacturers in these sectors are urgently seeking alternatives that offer price stability, ethical sourcing, and environmental sustainability.

The global omega-3 market itself was valued at approximately $3.3 billion in 2026 and is projected to surge to $5.4 billion by 2033. Because Algiecel operates within controlled indoor environments using captured industrial $textCO_2$, it completely bypasses oceanic fluctuations, overfishing regulations, and climatic shocks. For European manufacturers, this localized, Danish-produced supply chain represents a vital insulation layer against global supply chain disruptions.

Official Responses: Industry Leaders Weigh In

The inauguration of the Kalundborg facility drew praise from public officials, biotechnology pioneers, and corporate leadership alike, all emphasizing the power of cross-sector collaboration and circular economies.

Susanne Palsten Buchardt, Chief Executive Officer of Algiecel, stated:

"Our customers are looking for a scalable, high-quality, and sustainable alternative to the fish oil they are sourcing today. Algiecel is on a path to deliver just that. We’ve run our pilot reactor for more than 10,000 operational hours, and the biology performs as we designed it to. At a moment when fish oil supply is under real pressure, this facility is where we prove we can deliver a reliable alternative, produced under industrial conditions, at the volumes our customers need. It’s the starting platform we’ll use to scale further as demand grows."

Ghita Hansen, Vice President of Enzyme Production Denmark at Novonesis, remarked:

"Kalundborg shows what happens when companies work together to get more value from shared infrastructure, side-streams, and industrial expertise. It creates the conditions for new technologies to scale faster than they could alone. Algiecel’s new facility is a strong example of that."

Jan Lysgaard Thomsen, Municipal Director at Kalundborg Municipality, added:

"Algiecel’s investment in Kalundborg shows what happens when a small country backs big ideas. Denmark’s strength in biosolutions and our circular-economy approach are coming together here—good news for jobs and for Denmark’s place in the industries of the future."

Implications: Redefining Marine Ingredients for the Future

The opening of Algiecel’s Kalundborg plant carries profound implications for multiple industries, extending far beyond the borders of Denmark.

1. Decoupling from Marine Exploitation

For decades, industries requiring omega-3s and marine lipids have been inextricably linked to marine ecosystems. Overfishing, shifting ocean temperatures, and regulatory restrictions have made this dependence increasingly precarious. By successfully scaling microalgae production using industrial waste streams ($textCO_2$), companies like Algiecel prove that high-value marine ingredients can be synthesized without drawing a single pound of biomass from the world’s oceans.

2. The Rise of Industrial Symbiosis

The choice of Kalundborg is no accident. Kalundborg is globally renowned for its industrial symbiosis model, where the waste or byproduct of one enterprise serves as the raw material for another. By tapping directly into Novonesis’ site and utilizing a local biogas plant’s captured $textCO_2$, Algiecel embodies the next generation of manufacturing: one where carbon emissions are not merely offset, but utilized as a productive input to create valuable commercial commodities.

3. Transforming Pet Food and Cosmetics

Pet owners and beauty consumers are increasingly demanding transparent, sustainable, and ethically sourced ingredients. Pet food brands, which rely heavily on omega fatty acids for canine and feline joint, skin, and coat health, have long struggled with the carbon footprint and sustainability optics of marine-derived oils. Algiecel’s targeted 12-tonne annual output entering the market in 2027 will provide these consumer-facing brands with a compelling, green-certified selling point.

4. A Blueprint for Modular GreenTech Scaling

Many green technologies fail because they require massive, upfront capital expenditures to build monolithic, unproven industrial plants. Algiecel’s modular approach—replicating standardized reactor units rather than redesigning custom mega-facilities—offers a blueprint for how climate-tech startups can de-risk their expansion. Backed by seasoned veterans like Tove Feld and Mette Ingeman Pedersen, Algiecel is well-positioned to serve as a case study in how agile biology meets heavy industrial execution.

As the facility ramps up operations toward its 2027 production targets, the eyes of the global biotechnology sector will remain fixed on Kalundborg. In an era defined by resource scarcity and climate volatility, Algiecel’s microalgae reactors may well represent the blueprint for a more resilient, sustainable industrial future.